Foresite Capital Management Iv is an investment fund managing more than $149 billion ran by James Tananbaum. There are currently 4 companies in Mr. Tananbaum’s portfolio. The largest investments include Pharvaris N.v. and Kura Oncology Inc, together worth $119 billion.
As of 6th August 2024, Foresite Capital Management Iv’s top holding is 4,293,854 shares of Pharvaris N.v. currently worth over $80.7 billion and making up 54.2% of the portfolio value.
In addition, the fund holds 1,849,947 shares of Kura Oncology Inc worth $38.1 billion, whose value fell 2.6% in the past six months.
The third-largest holding is Syndax Pharmaceuticals Inc worth $18 billion and the next is Lyell Immunopharma, Inc. worth $12.1 billion, with 8,325,000 shares owned.
Currently, Foresite Capital Management Iv's portfolio is worth at least $149 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Foresite Capital Management Iv office and employees reside in Larkspur, California. According to the last 13-F report filed with the SEC, James Tananbaum serves as the Managing Member at Foresite Capital Management Iv.
In the most recent 13F filing, Foresite Capital Management Iv revealed that it had increased its stake in
Pharvaris N.v. and bought 255,012 additional shares worth around .
On the other hand, there are companies that Foresite Capital Management Iv is getting rid of from its portfolio.
Foresite Capital Management Iv closed its position in Kinnate Biopharma on 13th August 2024.
It sold the previously owned 9,671,643 shares for $25.7 billion.
The two most similar investment funds to Foresite Capital Management Iv are Eliot Finkel Investment Counsel and Godshalk Welsh Capital Management. They manage $149 billion and $149 billion respectively.
Foresite Capital Management Iv’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 37.7% of
the total portfolio value.
The fund focuses on investments in the United States as
50.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.05 billion.
These positions were updated on August 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Pharvaris N.v. |
6.31%
4,293,854
|
$80,724,455,000 | 54.23% |
| Kura Oncology Inc |
No change
1,849,947
|
$38,090,409,000 | 25.59% |
| Kinnate Biopharma Inc. |
Closed
9,671,643
|
$25,726,570,000 | |
| Syndax Pharmaceuticals Inc |
No change
875,000
|
$17,963,750,000 | 12.07% |
| Lyell Immunopharma, Inc. |
No change
8,325,000
|
$12,071,250,000 | 8.11% |
| No transactions found | |||
| Showing first 500 out of 5 holdings | |||